Nos publications
Mise à jour novembre 2023
Pagination
- Page précédente
- Page 37
- Page suivante
Title Trier par ordre décroissant | Authors | Year | Journal | Link to Article | Intended Audience | Purpose |
---|---|---|---|---|---|---|
Subarachnoid hemorrhage admissions retrospectively identified using a prediction model | English SW, McIntyre L, Fergusson D, Turgeon A, dos Santos MP, Lum C, Chassé M, Sinclair J, Forster A, van Walraven C | 2016 | Neurology | View Subarachnoid hemorrhage admissions retrospectively identified using a prediction model | Health care providers | Clinical research |
Subunit-directed click coupling via doubly cross-linked hemoglobin efficiently produces readily purified functional bis-tetrameric oxygen carriers | Singh S, Dubinsky-Davidchik IS, Yang Y, Kluger R | 2015 | Org Biomol Chem | View Subunit-directed click coupling via doubly cross-linked hemoglobin efficiently produces readily purified functional bis-tetrameric oxygen carriers | Researchers | Basic research |
Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model | Xu X, Chen D, Ye X, Xia W, Xu Y, Chen Y, Shao Y, Deng J, Ding H, Liu J, Wang J, Ni H, Fu Y, Santoso S | 2021 | Blood | View Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model | Researchers | Basic research |
Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody | Shao L, Wu Y, Zhou H, Qin P, Ni H, Peng J, Hou M | 2014 | Platelets | View Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody | Health care providers | Clinical research |
Suicidal death of erythrocytes in cancer and its chemotherapy: A potential target in the treatment of tumor-associated anemia | Lang E, Bissinger R, Qadri SM, Lang F | 2017 | Int J Cancer | View Suicidal death of erythrocytes in cancer and its chemotherapy: A potential target in the treatment of tumor-associated anemia | Researchers | Basic research |
Summary of adverse transfusion reactions 2017-2022 | Yan M | 2022 | Blood.ca website | View Summary of adverse transfusion reactions 2017-2022 | Blood operators | Benchmarking and standard setting |
Supernatant reduction of stored gamma?irradiated red blood cells minimizes potentially harmful substances present in transfusion aliquots for neonates | Serrano K, Pambrun C, Levin E, Devine DV | 2017 | Transfusion | View Supernatant reduction of stored gamma?irradiated red blood cells minimizes potentially harmful substances present in transfusion aliquots for neonates | Health care providers | New or improved product or process |
Surveillance report | O'Brien SF | 2022 | Blood.ca website | View Surveillance report | Blood operators | Benchmarking and standard setting |
Surveillance Report 2012 | O'Brien SF | 2014 | Blood.ca website | View Surveillance Report 2012 | Other | Other |
Surveillance Report 2013 | O'Brien SF | 2014 | Blood.ca website | View Surveillance Report 2013 | Other | Other |
Surveillance Report 2014 | O'Brien SF | 2015 | Blood.ca website | View Surveillance Report 2014 | Other | Other |
Surveillance Report 2015 | O'Brien SF | 2015 | Blood.ca website | View Surveillance Report 2015 | Other | Other |
Surveillance report 2016 | O'Brien SF | 2017 | Blood.ca website | View Surveillance report 2016 | Other | Benchmarking and standard setting |
Surveillance Report 2017 | O'Brien S | 2018 | Blood.ca website | View Surveillance Report 2017 | Other | Other |
Surveillance Report 2018 | O'Brien S | 2019 | Blood.ca website | View Surveillance Report 2018 | Health care providers | Benchmarking and standard setting |
Surveillance report 2020 | O'Brien S | 2021 | Blood.ca website | View Surveillance report 2020 | Health care providers | Benchmarking and standard setting |
Survey for bacterial testing of platelet components in Latin America | Ramirez-Arcos S, McDonald CP, Benjamin RJ, for the ISBT Working Party Transfusion Transmitted Infectious Diseases Bacterial Subgroup | 2017 | ISBT Sci Ser | View Survey for bacterial testing of platelet components in Latin America | Blood operators | New or improved product or process |
Survey of blood centre readiness regarding removal of DEHP from blood bag sets: The BEST Collaborative Study | Razatos A, Acker JP, de Korte D, Bégué S, Noorman F, Doyle B, Zia M, Min K, The Biomedical Excellence for Safer Transfusion Collaborative | 2022 | Vox Sang | View Survey of blood centre readiness regarding removal of DEHP from blood bag sets: The BEST Collaborative Study | Researchers | New or improved product or process |
Sustained Depletion of FXIII-A by Inducing Acquired FXIII-B Deficiency | Strilchuk AW, Meixner SC, Leung J, Safikhan N, Kulkarni JA, Russell HM, van der Meel R, Sutherland MR, Owens AP, Palumbo J, Conway EM, Pryzdial EL, Cullis P, Kastrup CJ | 2020 | Blood | View Sustained Depletion of FXIII-A by Inducing Acquired FXIII-B Deficiency | Researchers | Basic research |
Sustained expression of coagulation Factor IX by modified cord blood-derived mesenchymal stromal cells | Dodd M, Marquez-Curtis L, Janowska-Wieczorek A, Hortelano G | 2014 | J Gene Med | View Sustained expression of coagulation Factor IX by modified cord blood-derived mesenchymal stromal cells | Researchers | Basic research |
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists | Ghadaki B, Nazi I, Kelton JG, Arnold DM | 2013 | Transfusion | View Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists | Health care providers | Clinical research |
Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics | Nummi V, Lehtinen AE, Iorio A, Szanto T, Lassila R | 2022 | Haemophilia | View Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics | Researchers | Clinical research |
Switching to extended half-life products in Canada - preliminary data | Keepanasseril A, Stoffman J, Bouskill V, Carcao M, Iorio A, Jackson S | 2017 | Haemophilia | View Switching to extended half-life products in Canada - preliminary data | Health care providers | Clinical research |
Syndrome respiratoire aigu post-transfusionnel (TRALI) | Petraszko T | 2019 | Blood.ca website | View Syndrome respiratoire aigu post-transfusionnel (TRALI) | Researchers | Clinical research |
Syndrome respiratoire aigu post-transfusionnel (TRALI) | Gupta A, Yan M | 2021 | Blood.ca website | View Syndrome respiratoire aigu post-transfusionnel (TRALI) | Health care providers | Benchmarking and standard setting |
Synergistic effects of liposomes, trehalose, and hydroxyethyl starch for cryopreservation of human erythrocytes | Stoll C, Holovati JL, Acker JP, Wolkers WF | 2012 | Biotechnol Prog | View Synergistic effects of liposomes, trehalose, and hydroxyethyl starch for cryopreservation of human erythrocytes | Researchers | New or improved product or process |
Synthesis and evaluation of linear CuAAC-oligomerized antifreeze neo-glycopeptides | van der Wal S, Capicciotti CJ, Rontogianni S, Ben RN, Liskamp RMJ | 2014 | MedChemComm | View Synthesis and evaluation of linear CuAAC-oligomerized antifreeze neo-glycopeptides | Researchers | Basic research |
Synthesis of Highly Biocompatible and Temperature-Responsive Physical Gels for Cryopreservation and 3D Cell Culture | Nagao M, Sengupta J, Diaz-Dussan D, Adam M, Wu M, Acker J, Ben R, Ishihara K, Zeng H, Miura Y, Narain R | 2018 | ACS Appl Bio Mater | View Synthesis of Highly Biocompatible and Temperature-Responsive Physical Gels for Cryopreservation and 3D Cell Culture | Researchers | Basic research |
Synthesis of peptides and glycopeptides with polyproline II helical topology as potential antifreeze molecules | Corcilius L, Santhakumar G, Stone RS, Capicciotti CJ, Joseph S, Matthews JM, Ben RN, Payne RJ | 2013 | Bioorg Med Chem | View Synthesis of peptides and glycopeptides with polyproline II helical topology as potential antifreeze molecules | Researchers | Basic research |
Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism | Patel P, Patel P, Bhatt M, Braun C, Begum H, Nieuwlaat R, Khatib R, Martins CC, Zhang Y, Etxeandia-Ikobaltzeta I, Varghese J, Alturkmani H, Bahaj W, Baig M, Kehar R, Mustafa A, Ponnapureddy R, Sethi A, Thomas M, Wooldridge D, Lim W, Bates SM, Lang E, Le Gal G, Haramati LB, Kline J, Righini M, Wiercioch W, Schünemann H, Mustafa RA | 2021 | Blood Adv | View Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism | Researchers | Clinical research |
Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late? | Kirkham AM, Bailey AJM, Shorr R, Lalu MM, Fergusson DA, Allan DS | 2023 | Cytotherapy | View Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late? | Researchers | Clinical research |
Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials | Linkins L, Hu G, Warkentin TE | 2018 | Res Pract Thromb Haemost | View Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials | Researchers | Clinical research |
Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin | MacIsaac J, Siddiqui R, Jamula E, Li N, Baker S, Webert KE, Evanovitch D, Heddle NM, Arnold DM | 2018 | Transfusion | View Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin | Researchers | Clinical research |
Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey | Kahale LA, Diab B, Brignardello-Petersen R, Agarwal A, Mustafa RA, Kwong J, Neumann I, Li L, Lopes LC, Briel M, Busse JW, Iorio A, Vandvik PO, Alexander PE, Guyatt G, Akl EA | 2018 | J Clin Epidemiol | View Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey | Researchers | Other |
Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies | Shih AW, Liu A, Elsharawi R, Crowther MA, Cook RJ, Heddle NM | 2018 | Transfusion | View Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies | Researchers | Clinical research |
Systematic Scoping Review of Studies Reporting Unexpected Donor-Derived Abnormalities from Recipients of Allogeneic Hematopoietic Cell Transplantation: A Proposed Framework for Donor Disclosure | Candeliere J, Kirkham AM, Shorr R, Morris G, Berardi P, Seftel MD, Allan DS | 2022 | Cell Ther Transplant | View Systematic Scoping Review of Studies Reporting Unexpected Donor-Derived Abnormalities from Recipients of Allogeneic Hematopoietic Cell Transplantation: A Proposed Framework for Donor Disclosure | Health care providers | New or improved product or process |
Système Diego : l’anticorps anti-Dia | Meunier D, Peng S, Clarke G | 2019 | Blood.ca website | View Système Diego : l’anticorps anti-Dia | Health care providers | Benchmarking and standard setting |
Système Diego : l’anticorps anti-Wra | Meunier D, Peng S, Clarke G | 2019 | Blood.ca website | View Système Diego : l’anticorps anti-Wra | Health care providers | Benchmarking and standard setting |
Système Kell : l’anticorps anti-Jsa | Meunier D, Peng S, Clarke G | 2019 | Blood.ca website | View Système Kell : l’anticorps anti-Jsa | Health care providers | Benchmarking and standard setting |
Système Kell : l’anticorps anti-Kpa | Peng S, Meunier D | 2019 | Blood.ca website | View Système Kell : l’anticorps anti-Kpa | Health care providers | Benchmarking and standard setting |
Système Lewis : les anticorps anti-Lewis | Peng S, Meunier D | 2019 | Blood.ca website | View Système Lewis : les anticorps anti-Lewis | Health care providers | Benchmarking and standard setting |
Système Lutheran : l’anticorps anti-Lua | Meunier D, Peng S, Clarke G | 2019 | Blood.ca website | View Système Lutheran : l’anticorps anti-Lua | Health care providers | Benchmarking and standard setting |
Système MNS : l’anticorps anti-M | Clarke G, Côté J, Lane D | 2019 | Blood.ca website | View Système MNS : l’anticorps anti-M | Health care providers | Benchmarking and standard setting |
Système Rhésus : l’anticorps anti-Cw | Meunier D, Peng S, Clarke G | 2019 | Blood.ca website | View Système Rhésus : l’anticorps anti-Cw | Health care providers | Benchmarking and standard setting |
Système Rhésus : l’anticorps anti-V | Meunier D, Peng S, Clarke G | 2019 | Blood.ca website | View Système Rhésus : l’anticorps anti-V | Health care providers | Benchmarking and standard setting |
T cell-mediated autoimmunity in immune thrombocytopenia | Vrbensky JR, Nazy I, Clare R, Larché M, Arnold DM | 2022 | Eur J Haematol | View T cell-mediated autoimmunity in immune thrombocytopenia | Researchers | Clinical research |
T Regulatory Cells and Dendritic Cells Protect Against Transfusion-Related Acute Lung Injury via IL-10 | Kapur R, Kim M, Aslam R, McVey MJ, Tabuchi A, Luo A, Liu J, Li Y, Shanmugabhavananthan S, Speck ER | 2017 | Blood | View T Regulatory Cells and Dendritic Cells Protect Against Transfusion-Related Acute Lung Injury via IL-10 | Researchers | Basic research |
TACO-BEL-3: a feasibility study and a retrospective audit of diuretics for patients receiving blood transfusion at ten hospitals | Khandelwal A, Lin Y, Cserti-Gazdewich C, Al Moosawi M, Armali C, Arnold D, Callum J, Dallas KL, Lieberman L, Pavenski K, Rioux-Massé B, Shehata N, Shih AW, Pendergrast J | 2020 | Vox Sang | View TACO-BEL-3: a feasibility study and a retrospective audit of diuretics for patients receiving blood transfusion at ten hospitals | Health care providers | Clinical research |
Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort | Feldman BM, Rivard GE, Babyn P, Wu JKM, Steele M, Poon M-C, Card RT, Israels SJ, Laferriere N, Gill K, Chan AK, Carcao M, Klaassen RJ, Cloutier S, Price VE, Dover S, Blanchette VS | 2018 | Lancet Haematol | View Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort | Health care providers | Clinical research |
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates | Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M | 2017 | Thromb Haemost | View Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates | Health care providers | Clinical research |